Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Collaboration Needed To Ensure Access To Orphan Drugs – Express Scripts Exec

This article was originally published in The Pink Sheet Daily

Executive Summary

In an effort to ensure that there is access to high-priced drugs that treat rare diseases, relevant stakeholders, including manufacturers, payers, patients and physicians, need to come together and collaborate on access solutions that meet the needs of all parties, Express Scripts VP of Pharma Strategies and Account Management Bill Martin tells NORD/DIA conference.

Advertisement

Related Content

Rare Disease Drugs Deserve Lower Cost Sharing In Part D, McClellan Says
Pricing Rare Disease Drugs Requires Care As Payers Increase Scrutiny
Alexion’s Soliris Blood Treatment Will Cost Almost $400,000 Per Year

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel